<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html dir="ltr" xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml">
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>

<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<!-- 
	This website is powered by TYPO3 - inspiring people to share!
	TYPO3 is a free open source Content Management Framework initially created by Kasper Skaarhoj and licensed under GNU/GPL.
	TYPO3 is copyright 1998-2015 of Kasper Skaarhoj. Extensions are copyright of their respective owners.
	Information and contribution at http://typo3.org/
-->



<title>INHN: Bulletin 15 : Alfred Pletscher Autobiography – On the Eve of the Birth of the Neurotransmitter Era in Biological Psychiatry</title>
<meta name="generator" content="TYPO3 4.5 CMS" />

<link rel="stylesheet" type="text/css" href="IMAGES/STYLESHEET_9B1E31873F2366.CSS?1645000983" media="all" />



<script src="IMAGES/JAVASCRIPT_93077BB238F3E1.JS?1645000982" type="text/javascript"></script>


<link href="IMAGES/LAYOUT_3COL_STANDARD.CSS" rel="stylesheet" type="text/css" /><!--[if lte IE 7]><link href="fileadmin/styles/patches/../01_layouts_basics/css/patches/patch_3col_standard.css" rel="stylesheet" type="text/css" /><![endif]-->
<meta name="DC.title" content="Bulletin 15 : Alfred Pletscher Autobiography – On the Eve of the Birth of the Neurotransmitter Era in Biological Psychiatry" />
<meta name="description" content="INHN" />
<meta name="DC.Description" content="INHN" />
<meta name="keywords" content="International Network for the History of Neuropsychopharmacology" />
<meta name="DC.Subject" content="International Network for the History of Neuropsychopharmacology" />
<meta name="copyright" content="Copyright INHN 2012-14" />
<meta name="DC.Rights" content="Copyright INHN 2012-14" />
<meta http-equiv="content-language" content="en" />
<meta name="DC.Language" scheme="NISOZ39.50" content="en" />
<link rev="made" href="mailto:inhn@inhn.org" />
<meta http-equiv="reply-to" content="inhn@inhn.org" />
<meta name="author" content="Gregers Wegener" />
<meta name="DC.Creator" content="Gregers Wegener" />
<meta name="rating" content="General" />
<meta name="date" content="2019-03-12T16:37:32+00:00" />
<meta name="DC.date" content="2019-03-12T16:37:32+00:00" />
<meta name="robots" content="index,follow" />
<meta name="revisit-after" content="7" />
<link rel="start" href="INDEX681A.HTM?id=1" />
<link rel="up" href="INDEX768D.HTM?id=2359" />
<link rel="next" href="INDEX6102.HTM?id=2483" />
<link rel="prev" href="INDEXD4A9_2.HTM?id=2463" />
<link rel="canonical" href="INDEXD5AC.HTM?id=2474" />



</head>
<body id="pageUID-2474">


<div id="page_margins">
	<div id="page">
		<div id="header"><div class="tx-macinasearchbox-pi1">
		
<form action="https://inhn.org/index.php?id=5&amp;L=0" method="post" name="searchform" id="searchform">
<input name="tx_indexedsearch[sword]" type="text" value="Enter search word..." onclick="this.value=''" onblur="this.value='Enter search word...'" /><br />
<input type="hidden" name="tx_indexedsearch[_sections]" value="0" />
<input type="hidden" name="tx_indexedsearch[pointer]" value="0" />
<input type="hidden" name="tx_indexedsearch[ext]" value="0" />
<input type="hidden" name="tx_indexedsearch[lang]" value="0" />
</form>

	</div>
	<div id="topnav"><a class="skip" href="#navigation" title="Direkt zur Navigation springen">Zur Navigation springen</a><span class="hideme">.</span><a class="skip" href="#content" title="Direkt zum Content springen">Zum Content springen</a><span class="hideme">.</span><a href="INDEX3A9F.HTM?id=6" target="_self">Sitemap</a>&nbsp;&#124;&nbsp;<a href="INDEXD61C.HTM?id=5" target="_self">Search</a>&nbsp;&#124;&nbsp;<a href="INDEX65E4.HTM?id=kontakt" target="_self">Contact</a>&nbsp;&#124;&nbsp;<a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a></div><a href="INDEX2999.HTM?id=202"><img class="headImg1" src="IMAGES/COMPANY_LOGO.GIF" alt="" title="Home" width="598" height="100" /></a></div>
		<div id="nav"><a id="navigation" name="navigation"></a><div id="nav_main" class="hlist"><ul><li id="current"><a href="INDEX2999.HTM?id=202" target="_self"><span>Home</span></a></li><li><a href="INDEX7EFD.HTM?id=479" target="_self"><span>Dictionary</span></a></li><li><a href="INDEX3E5C.HTM?id=374" target="_self"><span>Drugs</span></a></li><li><a href="INDEXDBB1.HTM?id=565" target="_self"><span>Photos</span></a></li><li><a href="INDEXD919.HTM?id=342" target="_self"><span>Profiles</span></a></li><li><a href="INDEXAF9F.HTM?id=355" target="_self"><span>Controversies</span></a></li><li><a href="INDEXD122.HTM?id=641" target="_self"><span>Discoveries</span></a></li><li><a href="INDEX1F24.HTM?id=384" target="_self"><span>Books</span></a></li><li><a href="INDEX3958.HTM?id=467" target="_self"><span>Biographies</span></a></li><li><a href="INDEX677F.HTM?id=642" target="_self"><span>Perspectives</span></a></li><li><a href="INDEX8C00.HTM?id=343" target="_self"><span>Archives</span></a></li><li><a href="INDEX06CB.HTM?id=368" target="_self"><span>Ebooks</span></a></li><li><a href="INDEXA1F1.HTM?id=1755" target="_self"><span>Collated</span></a></li><li><a href="INDEXDF25.HTM?id=4128" target="_self"><span>Multilingual Project</span></a></li><li><a href="INDEXABE4.HTM?id=3884" target="_self"><span>INHN Publisher</span></a></li></ul></div></div>
		<div id="main">
			<div id="teaser" class="clearfix"><div class="rootline">You are here: <a href="INDEX2999.HTM?id=202" target="_self">Home</a>&nbsp;/&nbsp;<a href="INDEX3F39.HTM?id=1016" target="_self">Central Office (Cordoba Unit)</a>&nbsp;/&nbsp;<a href="INDEXC279.HTM?id=1659" target="_self">EDUCATION</a>&nbsp;/&nbsp;<a href="INDEX768D.HTM?id=2359" target="_self">Thomas A. Ban Neuropsychopharmacology in Historical Perspective - Education in the Field in the Post-Neuropsychopharmacology Era</a>&nbsp;/&nbsp;Bulletin 15 : Alfred Pletscher Autobiography – On the Eve of the Birth of the Neurotransmitter Era in Biological Psychiatry</div><div class="langMenu"><div class="tx-srlanguagemenu-pi1">
		
	</div>
	</div></div>
			<div id="col1">
				<div id="col1_content" class="clearfix">
					<ul id="submenu"><li id="title">Home</li><li><a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a><span class="hidden">.</span></li><li><a href="INDEXC104.HTM?id=854" target="_self">Towards education</a><span class="hidden">.</span></li><li><a href="INDEX3F39.HTM?id=1016" target="_self">Central Office (Cordoba Unit)</a><span class="hidden">.</span><ul><li><a href="INDEXEC89.HTM?id=1265" target="_self">Carlos Morra: Central Office</a></li><li><a href="INDEXF6AE.HTM?id=1234" target="_self">Administrative Unit by Leon S. Morra</a></li><li><a href="INDEXA81B.HTM?id=1233" target="_self">Carlos Morra: Chronological list of essential publications</a></li><li><a href="INDEXFC5C.HTM?id=3915" target="_self">Carlos Morra: Guide for Authors</a></li><li><a href="INDEX7A09.HTM?id=1123" target="_self">Thomas A. Ban: Recommended additions</a></li><li><a href="INDEX15CB.HTM?id=1587" target="_self">ADMINISTRATIVE UNIT</a><span class="hidden">.</span></li><li><a href="INDEXC279.HTM?id=1659" target="_self">EDUCATION</a><span class="hidden">.</span><ul><li><a href="INDEX768D.HTM?id=2359" target="_self">Thomas A. Ban Neuropsychopharmacology in Historical Perspective - Education in the Field in the Post-Neuropsychopharmacology Era</a><span class="hidden">.</span><ul><li><a href="INDEX114E.HTM?id=2360" target="_self">Bulletin 1: Educational Series 2. Jacques-Joseph Moreau de Tours.</a></li><li><a href="INDEX9E33.HTM?id=2367" target="_self">Bulletin 2 : Educational Series 2.Prologue</a></li><li><a href="INDEX1338.HTM?id=2375" target="_self">Bulletin 3 : Educational Series 2.  Vignette 1 Overview of the series: An Oral History of Neuropsychopharmacology</a></li><li><a href="INDEXF2B4.HTM?id=2385" target="_self">Bulletin 4 : Educational Series 2. Chapter 1: John Dalton’s atomic theory and drugs in psychiatry in the 19th century</a></li><li><a href="INDEXAEB2.HTM?id=2388" target="_self">Educational Series 2. Bulletin 5. Vignette 2: Sedatives in the second part of the 19th century</a></li><li><a href="INDEX8D36.HTM?id=2399" target="_self">Educational Series 2. Bulletin 6, Chapter 2: From William Cullen’s “neuroses” to Johann Christian Reil’s “psychiaterie”</a></li><li><a href="INDEX05B0.HTM?id=2404" target="_self">Educational Series 2. Bulletin 7, Vignette 3: Classifications of insanity in the late 18th and early 19th century</a></li><li><a href="INDEX525B.HTM?id=2414" target="_self">Educational Series 2. Bulletin 8, Chapter 3: Substances with an effect on consciousness</a></li><li><a href="INDEXA355.HTM?id=2422" target="_self">Educational Series 2. Bulletin 9 Vignette 4 :The isolation of morphine</a></li><li><a href="INDEX3BEE.HTM?id=2431" target="_self">Bulletin 10 : Reflexes of the brain</a></li><li><a href="INDEX8D24_2.HTM?id=2438" target="_self">Bulletin 11 : Sechenov’s re-evaluation of mental faculties and the brain</a></li><li><a href="INDEX796C.HTM?id=2451" target="_self">Bulletin 12 : Bayle’s discovery and the re-evaluation of the concept of dementia</a></li><li><a href="INDEX76A9_2.HTM?id=2458" target="_self">Bulletin 13 : Louis Sokoloff Autobiography – Regional mapping and imaging of the nervous system</a></li><li><a href="INDEXD4A9_2.HTM?id=2463" target="_self">Bulletin 14 : Joseph J. Schildkraut: Autobiography – The catecholamine hypothesis before and thereafter</a></li><li><strong>Bulletin 15 : Alfred Pletscher Autobiography – On the Eve of the Birth of the Neurotransmitter Era in Biological Psychiatry</strong></li><li><a href="INDEX6102.HTM?id=2483" target="_self">Bulletin 16 : Leo E. Hollister’s Interview of Julius Axelrod – The Uptake of Neurotransmitters and Psychoactive Drugs</a></li><li><a href="INDEXD4EC.HTM?id=2491" target="_self">Bulletin 17 : Thomas A. Ban’s Interview of Irwin J. Kopin – Metabolic disposition of catecholamines</a></li><li><a href="INDEXD604.HTM?id=2506" target="_self">Bulletin 18 : Thomas A. Ban’s Interview of Philip B. Bradley – Recording Electrical Activity from Cerebral Cortex and Subcortical Structures in Conscious Cats</a></li><li><a href="INDEXCD11.HTM?id=2521" target="_self">Bulletin 19 : From Conditioning and Psychiatry to Psychopharmacology*</a></li><li><a href="INDEX036F.HTM?id=2524" target="_self">Bulletin 20 : Conditioning and Psychiatry</a></li><li><a href="INDEXA67B.HTM?id=2533" target="_self">Bulletin 21 : Psychopharmacology</a></li><li><a href="INDEXA9EE_2.HTM?id=2543" target="_self">Bulletin 22 : Physiological patterns: A diagnostic test procedure based on the conditional reflex method</a></li><li><a href="INDEX8191.HTM?id=2551" target="_self">Bulletin 23 : Clinical pharmacology of psychotropic drugs</a></li><li><a href="INDEX0FE8.HTM?id=2562" target="_self">Bulletin 24 : Methodology and pitfalls in clinical testing of psychopharmacological drugs</a></li><li><a href="INDEX840B.HTM?id=2570" target="_self">Bulletin 25 : Toxicity and Adverse Reaction Studies with Neuroleptics and Antidepressants</a></li><li><a href="INDEX739E.HTM?id=2578" target="_self">Bulletin 26 : The effect of phenothiazines on the electrocardiogram</a></li><li><a href="INDEXF797.HTM?id=2586" target="_self">Bulletin 27 : Skin pigmentation, a rare side effect of chlorpromazine</a></li><li><a href="INDEX825E.HTM?id=2594" target="_self">Bulletin 28 : Ernst Feuchtersleben’s separation of psychosis from neurosis</a></li><li><a href="INDEXDC51.HTM?id=2603" target="_self">Bulletin 29 : Wilhelm Griesinger and Unitary Psychosis (Einheitpsychose)</a></li><li><a href="INDEX0C60.HTM?id=2612" target="_self">Bulletin 30 : Towards Neuropsychopharmacology in 1957</a></li><li><a href="INDEX76BD.HTM?id=2621" target="_self">Bulletin 31 : Fifty years CINP</a></li><li><a href="INDEX2103.HTM?id=2630" target="_self">Bulletin 32 : Fifty years ACNP</a></li><li><a href="INDEX6B55.HTM?id=2638" target="_self">Bulletin 33 : Starting Up (Volume One): 1. The Interviews</a></li><li><a href="INDEXEDEF.HTM?id=2647" target="_self">Bulletin 34 : Starting Up (Volume One): 2. Psychiatry</a></li><li><a href="INDEX22AE.HTM?id=2656" target="_self">Bulletin 35 : Starting Up (Volume One): 3. Drugs</a></li><li><a href="INDEXC051.HTM?id=2665" target="_self">Bulletin 36 : Starting Up (Volume One): 4. Pharmacology</a></li><li><a href="INDEX3552.HTM?id=2674" target="_self">Bulletin 37 : Starting Up (Volume One):  5. Interviewees</a></li><li><a href="INDEXBF4E.HTM?id=2683" target="_self">Bulletin 38 : Neurophysiology (Volume Two): 1. Early Development</a></li><li><a href="INDEXF887.HTM?id=2692" target="_self">Bulletin 39 : Neurophysiology (Volume Two): 2. Interviewees Contributions</a></li><li><a href="INDEX7741.HTM?id=2700" target="_self">Bulletin 40 : Neuropharmacology (Volume Three): 1. Neurotransmitters</a></li><li><a href="INDEXC58E.HTM?id=2708" target="_self">Bulletin 41 : Neuropharmacology (Volume Three): 2. Psychotropic drugs</a></li><li><a href="INDEX917B.HTM?id=2717" target="_self">Bulletin 42 : Neuropharmacology (Volume Three): 3a. Contributions of Interviewees</a></li><li><a href="INDEXBBC9.HTM?id=2726" target="_self">Bulletin 43 : Neuropharmacology (Volume Three): 3b. Contributions of Interviewees</a></li><li><a href="INDEX5AFC.HTM?id=2734" target="_self">Bulletin 44 : Psychopharmacology (Volume Four): 1. Clinical methodology</a></li><li><a href="INDEX5441.HTM?id=2751" target="_self">Bulletin 45 : Psychopharmacology (Volume Four): 2a. Contributions of Interviewees</a></li><li><a href="INDEXBB17.HTM?id=2760" target="_self">Bulletin 46 : Psychopharmacology (Volume Four): 2b. Contributions of Interviewees</a></li><li><a href="INDEX9F22.HTM?id=2761" target="_self">Bulletin 47 : Psychopharmacology (Volume Four): 2c. Contributions of Interviewees</a></li><li><a href="INDEXEFAA.HTM?id=2770" target="_self">Bulletin 48 : Neuropsychopharmacology (Volume Five): 1.Model Psychosis</a></li><li><a href="INDEX0571.HTM?id=2778" target="_self">Bulletin 49 : Neuropsychopharmacology (Volume Five): 2. Psychotoxic metabolites</a></li><li><a href="INDEX5740.HTM?id=2787" target="_self">Bulletin 50 : Neuropsychopharmacology (Volume Five): 3. Psychopharmacology of Schizophrenia; Psychopharmacology of Depression; Endocrine Measures</a></li><li><a href="INDEX47D5.HTM?id=2795" target="_self">Bulletin 51 : Neuropsychopharmacology (Volume Five): 4a. Contributions of Interviewees</a></li><li><a href="INDEXEE5A_2.HTM?id=2801" target="_self">Bulletin 52 : Neuropsychopharmacology (Volume Five): 4b. Contributions of Interviewees</a></li><li><a href="INDEX59FE.HTM?id=2810" target="_self">Bulletin 53 : Neuropsychopharmacology (Volume Five): 4c. Contributions of Interviewees</a></li><li><a href="INDEX0E71.HTM?id=2820" target="_self">Bulletin 54 : Addiction (Volume Six): 1. Addiction Psychiatry</a></li><li><a href="INDEXAE91.HTM?id=2829" target="_self">Bulletin 55 : Addiction (Volume Six): 2. Substances of abuse</a></li><li><a href="INDEX9B7D.HTM?id=2837" target="_self">Bulletin 56 : Addiction (Volume Six): 3. Conditioning and addiction</a></li><li><a href="INDEX0047_2.HTM?id=2846" target="_self">Bulletin 57 : Addiction (Volume Six): 4a. Contributions of interviewees</a></li><li><a href="INDEX44BA.HTM?id=2854" target="_self">Bulletin 58 : Addiction (Volume Six): 4b. Contributions of interviewees.</a></li><li><a href="INDEX0F23.HTM?id=2863" target="_self">Bulletin 59 : Special Areas (Volume Seven): 1. Child Psychiatry</a></li><li><a href="INDEXAA86.HTM?id=2871" target="_self">Bulletin 60 : Special Areas (Volume Seven): 2. Geriatric Psychiatry</a></li><li><a href="INDEX9ECC.HTM?id=2883" target="_self">Bulletin 61 : Special Areas (Volume Seven): 3. Psychiatric diagnosis</a></li><li><a href="INDEX1EC3.HTM?id=2892" target="_self">Bulletin 62 : Special Areas (Volume Seven): 4. Pharmacokinetics</a></li><li><a href="INDEXBAEC.HTM?id=2902" target="_self">Bulletin 63 : Special Areas (Volume Seven): 5a. Contributions of Interviewees.</a></li><li><a href="INDEX38B7.HTM?id=2921" target="_self">Bulletin 64 : Special Areas (Volume Seven): 5b. Contributions of Interviewees</a></li><li><a href="INDEX54DB.HTM?id=2938" target="_self">Bulletin 65 : Special Areas (Volume Seven): 5c. Contributions of Interviewees</a></li><li><a href="INDEX5194.HTM?id=2952" target="_self">Bulletin 66 : Diverse Topics (Volume Eight): 1. Regulation, Ethics, Marketing and Education, Conflict of Interest</a></li><li><a href="INDEXF272.HTM?id=2960" target="_self">Bulletin 67 : Diverse Topics (Volume Eight): 2a. Interviewees Contributions</a></li><li><a href="INDEXCAF4.HTM?id=2969" target="_self">Bulletin 68 : Diverse Topics (Volume Eight): 2b. Interviewees Contributions</a></li><li><a href="INDEX8272.HTM?id=2979" target="_self">Bulletin 69 : Update (Volume Nine): 1. Pharmacogenetics and Genetics and Neuropsychopharmacology</a></li><li><a href="INDEXBD8C.HTM?id=2988" target="_self">Bulletin 70 : Update (Volume Nine): 2. Psychopathology and Nosology</a></li><li><a href="INDEX2A75.HTM?id=3004" target="_self">Bulletin 71 : Update (Volume Nine): 3a. Interviewee’s Contributions</a></li><li><a href="INDEX48C2.HTM?id=3021" target="_self">Bulletin 72 : Update (Volume 9) 3b. Interviewees contributions</a></li><li><a href="INDEX616E.HTM?id=3030" target="_self">Bulletin 73 : Volume 10. Postscript</a></li><li><a href="INDEX1D4A.HTM?id=3036" target="_self">Bulletin 74 : An Overview of Developments in Psychopharmacology and Neuropsychopharmacology</a></li><li><a href="INDEX2F0A.HTM?id=3048" target="_self">Bulletin 75 : The confounding of education with marketing</a></li><li><a href="INDEX1E85.HTM?id=3055" target="_self">Bulletin 76 : Towards a genetic era in neuropsychopharmacology</a></li><li><a href="INDEX5072.HTM?id=3062" target="_self">Bulletin 77 : The CODE System</a></li><li><a href="INDEXBB3A.HTM?id=3071" target="_self">Bulletin 78 : Nosologic Homotyping</a></li><li><a href="INDEX5262.HTM?id=3085" target="_self">Collated Bulletin 1: RDoC in Historical Perspective.</a></li><li><a href="INDEX8197.HTM?id=3094" target="_self">Collated Bulletin 2 : Neuropsychopharmacology and the Forgotten Language of Psychiatry</a></li><li><a href="INDEXCB60.HTM?id=3103" target="_self">Collated Bulletin 3 : In Historical Perspective: Peralta, Cuesta and their associate’s findings on the highest familiality of Leonhard’s Classification in Polynosologic Study</a></li><li><a href="INDEX55BE.HTM?id=3111" target="_self">Collated Bulletin 4: Thomas A. Ban: The Birth of a Medical Discipline: Psychiatry</a></li><li><a href="INDEX1328.HTM?id=3124" target="_self">Collated Bulletin 5: Thomas A. Ban: Conflict of Interest in Neuropsychopharmacology. Marketing vs. Education.</a></li><li><a href="INDEX9A64.HTM?id=3130" target="_self">Collated Bulletin 6: Edward Shorter: The QT interval and the Mellaril story</a></li><li><a href="INDEXC9E3.HTM?id=3143" target="_self">Collated Bulletin 7 : Thomas A. Ban: The Wernicke – Kleist – Leonhard Tradition with Special Reference to Mania, Melancholia and Manic – Depressive Psychosis</a><span class="hidden">.</span></li><li><a href="INDEX1124.HTM?id=3152" target="_self">Collated Bulletin 8 : Thomas A. Ban: The Birth of Drug Industry and Drugs with An Effect On Behavior</a></li><li><a href="INDEX1A41.HTM?id=3164" target="_self">Collated Bulletin 9 : Thomas A. Ban: From Melancholia to Depression</a></li><li><a href="INDEX4A53.HTM?id=3170" target="_self">Collated Bulletin 10 : Thomas A. Ban: The Year 1845</a></li><li><a href="INDEX4878.HTM?id=3182" target="_self">Collated Bulletin 11 : Joseph Knoll: The discovery of monoamine oxidase (MAO) enzymes</a><span class="hidden">.</span></li><li><a href="INDEX13FE.HTM?id=3200" target="_self">Collated Bulletin 12 : Samuel Gershon: Events and Memories</a></li><li><a href="INDEXBAD0.HTM?id=3287" target="_self">Collated Bulletin 13 : Paul Devenyi: Addictions are not treatable diseases and Pharmacotherapy of addiction not a success story.</a></li><li><a href="INDEX80F0.HTM?id=3297" target="_self">Collated Bulletin 14 : Janos Radó: The use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus</a></li><li><a href="INDEX7FB2.HTM?id=3305" target="_self">Collated Bulletin 15 : Per Bech:  Clinical Psychometrics</a></li><li><a href="INDEX2912.HTM?id=3312" target="_self">Collated Bulletin 16 : Martin M. Katz: Onset of clinical effects of antidepressants</a></li><li><a href="INDEX412B.HTM?id=3321" target="_self">Collated Bulletin 17 : Martin M. Katz: Depression and Drugs, a monograph  and Multivantaged vs Conventional Assessment, an essay</a></li><li><a href="INDEXB116.HTM?id=3330" target="_self">Collated Bulletin 18 : Per Bech:  Measurement-based care in mental disorders (New York: Springer; 2016) Foreword and Review</a></li><li><a href="INDEX8100.HTM?id=3338" target="_self">Collated Bulletin 19 : Donald F. Klein and John Davis: Diagnosis and Drug Treatment of Mental Disorders and Thomas A. Ban: Psychopharmacology in 1969</a></li><li><a href="INDEX7B0A.HTM?id=3345" target="_self">Collated Bulletin 20 : Thomas A. Ban: Schizophrenia in the Early 1970s</a></li><li><a href="INDEXAF2B.HTM?id=3355" target="_self">Collated Bulletin 21 : Thomas A. Ban, Marcelo Cetkovich-Bakmas, Ernst Franzek and Hector Warnes: Carl Wernicke’s “elementary symptoms” and “sejunction hypothesis”</a></li><li><a href="INDEXE783.HTM?id=3374" target="_self">Collated Bulletin 22 : Martin M. Katz: Clinical Trials of Antidepressants: How Changing the Model Can Uncover New, More Effective Molecules</a></li><li><a href="INDEX4AF0.HTM?id=3393" target="_self">Collated Bulletin 23 : Joseph Knoll: From the Theory of Active Reflexes to a Neurochemical Concept of Innate and Acquired Drive</a></li><li><a href="INDEXC922.HTM?id=3401" target="_self">Collated Bulletin 24 : Ildiko Miklya: The  History of Selegiline (-) Deprenyl the First Selective Inhibitor of B-Type Monoamine Oxidase and the First Synthetic Catecholaminergic Enhancer Substance</a></li><li><a href="INDEX5549.HTM?id=3411" target="_self">Collated Bulletin 25 : Joseph Knoll: The Discovery of the Enhancer Regulation in the Mammalian Brain and the Development of the Synthetic Enhancer Substances</a></li><li><a href="INDEXBEF3.HTM?id=3421" target="_self">Collated Bulletin 26 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology: Julius Axelrod, Frank Ayd, Frank Berger, Hans Berger and Hermann Blaschko</a></li><li><a href="INDEXDEB4.HTM?id=3428" target="_self">Collated Bulletin 27 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Charles Bradley, Philip B. Bradley, Bernard B. Brodie, John Cade and John Delay</a></li><li><a href="INDEX65AD.HTM?id=3436" target="_self">Collated Bulletin 28 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Edmundo Fischer, W. Horsley Gantt, Turan M. Itil, Hitoshi Itoh and Paul Kielholz</a></li><li><a href="INDEX9D53.HTM?id=3446" target="_self">Collated Bulletin 29 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Nathan S. Kline, Roland Kuhn, Heinz E. Lehmann, Laszlo Meduna and Dionisio Nieto Gomez</a></li><li><a href="INDEX05ED.HTM?id=3454" target="_self">Collated Bulletin 30 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Alfred Pletscher, Juri Saarma, Sydney Spector, Leo Sternbach, Edward Trautner and Joseph Wo</a></li><li><a href="INDEX51CB.HTM?id=3464" target="_self">Collated Bulletin 31 : Thomas A. Ban: Lithium. 1. Discovery of its therapeutic effect in psychiatry. Johan Schioldann, William T. Hammond and Carl Lange</a></li><li><a href="INDEX7AE6.HTM?id=3471" target="_self">Collated Bulletin 32 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective. 2. Introduction into treatment in psychiatry. Samuel Gershon: Profiles of John Cade and Edward Trautner</a></li><li><a href="INDEX9492.HTM?id=3479" target="_self">Collated Bulletin 33 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective. 3. Early Years. Samuel Gershon: First-Hand Accounts</a></li><li><a href="INDEX5A82.HTM?id=3489" target="_self">Collated Bulletin 34 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective</a></li><li><a href="INDEXBC82.HTM?id=3497" target="_self">Collated Bulletin 35 : Thomas A. Ban: Lithium. 4. Controversy. Barry Blackwell vs Paul Grof and Jules Angst</a></li><li><a href="INDEXE7C3.HTM?id=3506" target="_self">Collated Bulletin 36 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective 5. Turning point. Paul Grof and Johan Schioldann</a></li><li><a href="INDEXF857.HTM?id=3514" target="_self">Collated Bulletin 37 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective 6. Action. Janusz Rybakowski</a></li><li><a href="INDEX6E77.HTM?id=3523" target="_self">Collated Bulletin 38 : Thomas A. Ban: 7.  Diagnosis</a></li><li><a href="INDEX680B.HTM?id=3532" target="_self">Collated Bulletin 39 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective Dedication and Preface</a></li><li><a href="INDEX516F.HTM?id=3541" target="_self">Collated Bulletin 40 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective.</a></li><li><a href="INDEX1901.HTM?id=3550" target="_self">Collated Bulletin 41 : Peter R. Martin. Volume 1. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by Thomas A. Ban</a></li><li><a href="INDEXCA36.HTM?id=3558" target="_self">Collated Bulletin 42 : Peter R. Martin. Volume 2. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by Leo E. Hollister</a></li><li><a href="INDEXE728.HTM?id=3566" target="_self">Collated Bulletin 43 : Peter R. Martin. Volume 2. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by William E. Bunney, Jr.</a></li><li><a href="INDEX0343.HTM?id=3583" target="_self">Lehmann Collection 1 : Charles E. Cahn’s interview of Heinz E. Lehmann</a><span class="hidden">.</span></li><li><a href="INDEXAF7B.HTM?id=3591" target="_self">Lehmann Collection 2 : William E. Bunney’s interview of Heinz E. Lehmann</a></li><li><a href="INDEXC461.HTM?id=3599" target="_self">Lehmann Collection 3 : Heinz Edgar Lehmann by Barry Blackwell</a></li><li><a href="INDEXC5D4.HTM?id=3607" target="_self">Lehmann Collection 4 : Heinz Lehmann and Douglas Hospital by Charles C. Cahn</a></li><li><a href="INDEXEC5F.HTM?id=3616" target="_self">Lehmann Collection 5 : Heinz Edgar Lehmann’s research profile by Antonio E. Nardi.</a></li><li><a href="INDEXDB89.HTM?id=3624" target="_self">Lehmann Collection 6 : Heinz E. Lehmann by Edward Shorter.</a></li><li><a href="INDEXB434.HTM?id=3633" target="_self">Lehmann Collection 7 : Per Bech’s comment on Heinz E. Lehmann*</a></li><li><a href="INDEX1767.HTM?id=3641" target="_self">Lehmann Collection 8 : Paul Grof’s comment on Heinz E. Lehmann. A few personal recollections</a></li><li><a href="INDEX7BD1.HTM?id=3650" target="_self">Lehmann Collection 9 : Irwin J. Kopin’s comment on Heinz E. Lehmann.</a></li><li><a href="INDEXAE03.HTM?id=3661" target="_self">Lehmann Collection 10 : Mary and Philip Seeman's comment</a></li><li><a href="INDEXDDD3.HTM?id=3680" target="_self">Lehmann Collection 11 : A Tribute to Heinz Edgar Lehmann by Hector Warnes.</a></li><li><a href="INDEX42F1.HTM?id=3689" target="_self">Lehmann Collection 12 : Heinz Edgar Lehmann:  Publication</a></li><li><a href="INDEX8FD0.HTM?id=3698" target="_self">Lehmann Collection 13 :  Thomas A. Ban: My Personal Notes on Heinz Lehmann</a></li><li><a href="INDEXC658.HTM?id=3707" target="_self">Lehmann Collection 14 : Thomas A. Ban: Heinz E. Lehmann and Psychopharmacology</a></li><li><a href="INDEXB918.HTM?id=3717" target="_self">Lehmann Collection 15 : Thomas A. Ban: Towards a clinical methodology for neuropsychological research</a></li><li><a href="INDEXF57D.HTM?id=3726" target="_self">Lehmann Collection 16 : Heinz Edgar Lehmann</a></li><li><a href="INDEX1FC5.HTM?id=3734" target="_self">Lehmann Collection 17 : Heinz E. Lehmann: What is wrong with getting old?</a></li><li><a href="INDEX1A9C.HTM?id=3743" target="_self">Lehmann Collection 18 : Heinz E. Lehmann: Dreaming about Mental Health</a></li><li><a href="INDEXDC72.HTM?id=3753" target="_self">Lehmann Collection 19: Heinz E. Lehmann: Alcoholism, aggression and androgen function. Discussion of paper by Jack Mendelson</a></li><li><a href="INDEX7FE1.HTM?id=3761" target="_self">Lehmann Collection 20: Heinz E. Lehmann: Perspectives in Psychosurgery</a></li><li><a href="INDEX6E26.HTM?id=3770" target="_self">Lehmann Collection 21 : Heinz E. Lehmann: Discussion of the paper by Prof. P. Pichot:  The Treatment of Depression</a></li><li><a href="INDEX2F04.HTM?id=3778" target="_self">Lehmann Collection 22 : Heinz E. Lehmann: Harlem Valley Revisited</a></li><li><a href="INDEX8D36_2.HTM?id=3788" target="_self">Lehmann Collection 23 : Heinz E. Lehmann: Chlorpromazine: The Story of Phenothiazine Derivatives, Their Clinical Indications, the Incidence and Management of Untoward Effects and a Proposed Rational for Its Action</a></li><li><a href="INDEXC42B.HTM?id=3796" target="_self">Lehmann Collection 24 : Heinz E. Lehmann: The Anatomy of Research Funding</a></li><li><a href="INDEX7DC1.HTM?id=3804" target="_self">Lehmann Collection 25 : Program of Academic morning in honor of Dr. Heinz Lehmann</a></li><li><a href="INDEX212A.HTM?id=3814" target="_self">Lehmann Collection 26 : Heinz E. Lehmann: Types and Characteristics of Objective Measures of Psychopathology</a></li><li><a href="INDEX40D0.HTM?id=3877" target="_self">Classification of Functional Psychoses 1 : Preface and Recommended Reading</a></li><li><a href="INDEXF49C.HTM?id=3888" target="_self">Classification of Functional Psychoses 2 : Introduction</a></li><li><a href="INDEX12CF.HTM?id=3896" target="_self">Classification of Functional Psychoses 3 : ICD-9 and DSM-III</a></li><li><a href="INDEX93EE.HTM?id=3906" target="_self">Classification of Functional Psychoses 4: Classification of Mental Disorders and Psychopharmacology – Diagnostic Criteria for Research</a></li><li><a href="INDEX0CDC.HTM?id=3914" target="_self">Classification of Functional Psychoses 5: The KDK Budapest</a></li><li><a href="INDEX6A56.HTM?id=3923" target="_self">Classification of Functional Psychoses 6: One- and Two-Dimensional Diagnoses</a></li><li><a href="INDEX44FB.HTM?id=3933" target="_self">Classification of Functional Psychoses 7: Delusional Development and Delusional Psychoses</a></li><li><a href="INDEXA244.HTM?id=3942" target="_self">Classification of Functional Psychoses 8: Bayle’s Unitary Concept of Psychosis and Endogenous Psychoses</a></li><li><a href="INDEX76A8.HTM?id=3952" target="_self">Classification of Functional Psychoses 9: Affective Psychosis</a></li><li><a href="INDEXF554.HTM?id=3960" target="_self">Classification of Functional Psychoses 10: Empirical and Pragmatic Classifications of Depression</a></li><li><a href="INDEXB28B.HTM?id=3969" target="_self">Classification of Functional Psychoses 11: Schizophrenic Psychoses</a></li><li><a href="INDEXEE78.HTM?id=3977" target="_self">Classification of Functional Psychoses 12: Cycloid Psychoses</a></li><li><a href="INDEX79BA.HTM?id=3985" target="_self">Classification of Functional Psychoses 13: Conclusions</a></li><li><a href="INDEXFDAB.HTM?id=3994" target="_self">Classification of Functional Psychoses 14: References</a></li><li><a href="INDEXF3F8.HTM?id=4011" target="_self">Delcir da Costa’s comment on collating document</a></li><li><a href="INDEXFAD4.HTM?id=4030" target="_self">Dementia Differential Diagnosis 1991 : Contents</a></li><li><a href="INDEX05BB.HTM?id=4042" target="_self">Dementia Differential Diagnosis 1991 : Conceptual Development</a></li><li><a href="INDEXA331.HTM?id=4051" target="_self">Dementia Differential Diagnosis 1991 : Dementing Illnesses</a></li><li><a href="INDEXDEF5.HTM?id=4059" target="_self">Dementia Differential Diagnosis 1991 : Modified Concept</a></li><li><a href="INDEX4686.HTM?id=4068" target="_self">Dementia Differential Diagnosis 1991 : Diagnosing of Dementing Illness</a></li><li><a href="INDEXED54.HTM?id=4077" target="_self">Dementia Differential Diagnosis 1991 : References</a></li><li><a href="INDEX0D43.HTM?id=4132" target="_self">Methodology pitfalls of clinical testing of psychopharmaceutical</a></li><li><a href="INDEX9601.HTM?id=4140" target="_self">Mental health (Psychiatry) and pharmaceuticals in a historical perspective</a></li><li><a href="INDEX114D.HTM?id=4150" target="_self">Nosology in the teaching of psychiatry. Introduction</a></li><li><a href="INDEX4294.HTM?id=4158" target="_self">Towards a clinical methodology for neuropsychopharmacological research</a></li><li><a href="INDEXD825.HTM?id=4176" target="_self">Selective Drugs Versus Heterogeneous Diagnoses. Towards a New Methodology in Psychopharmacologic Research</a></li></ul></li><li><a href="INDEXC4F2.HTM?id=2324" target="_self">Per Bech: Members of the International Committee for the Prevention and Treatment of Depression in the mid-1980s</a></li><li><a href="INDEXC2D5.HTM?id=2299" target="_self">Per Bech and Wolfgang Rutz: The Story of the International Committee for the Prevention and Treatment of Depression</a></li><li><a href="INDEX9256.HTM?id=2371" target="_self">Peter R. Martin: Historical Dictionary of Addiction</a><span class="hidden">.</span></li><li><a href="INDEX527D.HTM?id=2648" target="_self">Amara McLaughlin-Harris: The Legal History of Psychoactive Drugs</a><span class="hidden">.</span></li><li><a href="INDEXFB23.HTM?id=2184" target="_self">Carlos Morra: An Educational Model in Psychiatry</a><span class="hidden">.</span></li><li><a href="INDEX9A07.HTM?id=2428" target="_self">Carlos Morra and Ernst Franzek: Psychopathological Symptoms</a><span class="hidden">.</span></li><li><a href="INDEX0793.HTM?id=3533" target="_self">Carlos Morra and Mateo Kreiker: Psychopathology</a><span class="hidden">.</span></li></ul></li></ul></li><li><a href="INDEX4710.HTM?id=3072" target="_self">INHN Publisher</a><span class="hidden">.</span></li><li><a href="INDEX7227.HTM?id=1114" target="_self">Programs</a><span class="hidden">.</span></li><li><a href="INDEXEAE0.HTM?id=1266" target="_self">Courses</a><span class="hidden">.</span></li><li><a href="INDEX86F6.HTM?id=1296" target="_self">Interviews</a><span class="hidden">.</span></li><li><a href="INDEXEF79.HTM?id=410" target="_self">Copyright Policy</a></li><li><a href="INDEX756E.HTM?id=437" target="_self">How to cite INHN</a></li><li><a href="INDEXCF6F.HTM?id=3373" target="_self">Website Table of Contents</a></li><li><a href="INDEXD254.HTM?id=2343" target="_self">Last Uploads</a></li></ul>
					
					<div class="textBelowMenu"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
				</div>
			</div>
			<div id="col2">
				<div id="col2_content" class="clearfix"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
			</div>
			<div id="col3">
			  <a id="content" name="content"></a>
				<div id="col3_content" class="clearfix">
					<div class="floatbox"><!--TYPO3SEARCH_begin--><!--DMAILER_SECTION_BOUNDARY_--><div id="c4301" class="csc-default"><h1><span style="font-weight: normal;">Thomas A. Ban<br />Neuropsychopharmacology in Historical Perspective<br /> Education in the Field in the Post-Neuropsychopharmacology Era</span><br /><b>&nbsp;<br /></b><b>Alfred Pletscher Autobiography – On the Eve of the Birth of the Neurotransmitter Era in Biological Psychiatry<br /></b><span style="font-weight: normal;">&nbsp;<br />Bulletin 15 </span></h1>
<p>&nbsp;</p>
<h2><b>Preamble</b></h2>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p>The story of serotonin and norepinephrine, the first monoamine neurotransmitters identified begins with the detection of a vasoconstrictor substance in the blood in the mid-1880s by Stevens and Lee (1884). The substance was crystallized from ox serum by Rapport, Green and Page (1948) and its chemical structure identified, in the late 1940s, as 5-hydroxytryptamine (5HT), referred to as serotonin. Independent of this development, in the mid-1930s Erspamer with Vialli (1937) extracted a substance from the enterochromaffin cells of the intestinal mucosa of rabbits, they referred to as enteramine. In the early 1950s Erspamer recognized that “enteramine” was a structurally-identical “indoleamine” with serotonin (Erspamer and Asero 1952). Then, in 1953, Twarog and Page demonstrated the presence of 5HT in the brain and one year later, in 1954, Amin, Crawford and Gaddum described its distribution in the brain. </p>
<p>Simultaneously with this development, but starting about 20 years later, in the early years of the 20<sup>th</sup> century, R.T. Elliott (1905) detected a substance at sympathetic nerve endings he referred to as “sympathin.” In the mid-1940s the substance was identified as noradrenaline (NA)/norepinephrine (NE<i>)</i> and separated by Ulf von Euler (1905-1983) from adrenaline/epinephrine (Euler1946).&nbsp; In 1954, the same year as Amin, Crawford and Gaddum described the distribution of 5HT in the brain, Marthe Vogt (1903–2003) reported on the concentration of NE in different parts of the brain in normal conditions and after the administration of drugs (Ban 2011; Vogt 1954). </p>
<p>Recognition of the function of monoamine oxidase (MAO), the enzyme involved in the oxidative deamination of monoamines is linked to the name of Felix Blaschko (1900–1993). While studying the metabolism of adrenaline in the mid-1930s Blaschko and his associates found that it was metabolized by “tyramine oxidase,” an enzyme first described in 1928 by MLC Hare in the liver (Blaschko, Schlossmann and Richter 1937a; Kopin 2006). Subsequently, they had also shown that it was the same enzyme that metabolized noradrenaline, dopamine and all aliphatic amines (Knoll 2014). Hence, they changed its name from “tyramine oxidase” to “amine oxidase.” Furthermore, in 1937 Blaschko, Schlossmann and Richter (1937b), provided further substantiation on the presence of the enzyme in the liver.&nbsp;&nbsp; In the same year, amine oxidase was also detected in the brain by Pugh and Quastel (1937). One year later, in 1938, after Albert Zeller’s separation of “diamine oxidase” from “amine oxidase,” the name of “amine oxidase” was changed to “monoamine oxidase” (MAO) to indicate that its function is restricted to the oxidative deamination of monoamines (Knoll 2014).</p>
<p>Developments which led to the introduction of substances with an inhibitory effect on the activity of the MAO enzyme began in1945 with V. Chorine’s discovery that nicotinamide had a bacteriostatic effect (Kopin 2006). The search that followed for related drugs that might be useful in the treatment of tuberculosis led, in the early 1950s, to the synthesis of isoniazid and iproniazid, its hydrazide derivative, by Fox and Gibbs (1953) at Hoffmann La Roche Laboratories in the USA (Pletscher 2006). It was noted that both energized patients and produced euphoria in tubercular patients with (Flaherty 1952). In 1952, antidepressant effects were reported with isoniazid by Delay, Laine and Buisson, and Robitzek, Selikoff and Orenstein. In the same year (1952) Zeller and his associates discovered that both isoniazid and iproniazid were inhibitors of the activity of the MAO enzyme (Zeller and Barsky 1952; Zeller, Barsky and Fouts 1952). From the two substances iproniazid was more potent. It was an irreversible inhibitor of MAO (Pletscher 2006).&nbsp;&nbsp; </p>
<p>Instrumental to further developments was the construction and introduction of the Aminco Bowman spectrophotofluorometer (SPEC<i>)</i> in 1955 with the necessary sensitivity to measure the concentration of neurotransmitter monoamines, such as NE and 5-HT and their metabolites in the brain (Bowman, Caulfield and Udenfriend 1955). The SPEC was ready for use in the laboratory of Bernard Brodie (1907–1989) at the National Institutes of Health (NIH) of the United States without delay.&nbsp;&nbsp;&nbsp; </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This was the state of affairs in March 1955 when Alfred Pletscher (1917-2006), an employee of Hoffmann La Roche, the company that developed isoniazid and iproniazid, joined Brodie’s Laboratory as a visiting scientist. His findings, with the employment of SPEC that the tranquilizing (sedative) action of reserpine, a substance that can arguably induce depression (See Bulletin 14) is associated with a dose dependent depletion of brain 5HT, reported with Brodie and Parkhurst Shore, in the same year (Pletscher, Brodie and Shore 1955) opened up worldwide research on the neurobiology of monoamine neurotransmitters and led ultimately to the monoamine hypotheses of affective disorders. His discovery that pre-treatment with iproniazid, a substance that can arguably induce elation, not only attenuated the tranquilizing (sedative) effect of reserpine, but reversed it by producing behavioral stimulation, provided the scientific rationale for the introduction of MAO inhibitors in the treatment of depression. It also heralded, in 1956, the beginning of the “neurotransmitter era,” the first epoch in the history of neuropsychopharmacology (Ban 2011; Ban and Ucha Udabe 2006; Besendorf and Pletscher 1956; Brodie, Pletscher and Shore 1956; Brodie, Shore and Pletscher 1956; Pletscher 1956; Pletscher, Shore and Brodie 1955, 1956; Sulser 2011). &nbsp;&nbsp;&nbsp;&nbsp; </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The autobiographic essay of Alfred Pletscher in which the story of his major contributions to biochemical neuropsychopharmacology in the 1950s are discussed was first published in 1998 with the title “On the eve of the neurotransmitter era in biological psychiatry” in The Rise of Psychopharmacology and the Story of CINP edited by Thomas A. Ban, David Healy and Edward Shorter. Parts of the story is also covered in one of Pletscher’s other autobiographic essays, published in 2004, with the title “From inside the pharmaceutical industry” in Reflections on Twentieth–Century Psychopharmacology by the same editors (Ban, Healy and Shorter 1996, 2004.) </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are also two interviews with Pletscher which contain information on his contributions to neuropsychopharmacology, one conducted by Ban and the other by Andrea Tone, both published in 2011, in volumes Three (Neuropharmacology, edited by Fridolin Sulser) and Nine (Update, edited by Barry Blackwell) in An Oral History of Neuropsychopharmacology, a series edited by Ban (Ban 2011; Blackwell 2011; Sulser 2011). &nbsp;</p>
<p><b>References:</b></p>
<p>Amin AH, Crawford TB, Gaddum JH. The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog.&nbsp; J Physiol 1954; 126: 596-618.</p>
<p>Ban TA. Psychopharmacology of Depression. New York: Karger; 1981. </p>
<p>Ban TA, editor. An Oral History of Neuropsychopharmacology The First Fifty Years Peer Interviews. Brentwood: American College of Neuropsychopharmacology; 2011.</p>
<p>Ban TA. Preface. In Ban TA, editor. An Oral History of Neuropsychopharmacology The First Fifty Years Peer Interviews. Volume Five (Neuropharmacology, editor Fridolin Sulser). Brentwood: American College of Neuropsychopharmacology; 2011, p. ix – xxx.</p>
<p>Ban TA, Healy D, Shorter E, editors. The Rise of Psychopharmacology and the Story of CINP. Budapest: Animula; 1996).</p>
<p>Ban TA, Healy D, Shorter E, editors. Reflections on Twentieth-Century Psychopharmacology. Budapest: Animula; 2004).</p>
<p>Ban TA, Ucha Udabe R, editors. The Neurotransmitter Era in Neuropsychopharmacology. Buenos Aires: Polemos; 2006.</p>
<p>Ban TA. Ucha Udabe R. Concluding remarks. In: Ban TA, Ucha Udabe R, editors. The Neurotransmitter Era in Neuropsychopharmacology. Buenos Aires: Polemos; 2006, p.265 -74.</p>
<p>Besendorf H, Pletscher A. <i>Beeinflussung zentrale Wirkungen von Reserpin und 5-Hydroxytryptamin durch Isonikotinsauerehydrazide</i>. Helv Physiol Acta 1956; 14: 383 - 90.&nbsp; </p>
<p>Blackwell B, editor. Update. (Ban TA, editor. An Oral History of Neuropsychopharmacology The First Fifty Years Peer Interviews. Volume Nine). Brentwood: American College of Neuropsychopharmacology; 2011.</p>
<p>Blaschko H, Richter D, Schlossmann H. The inactivation of adrenaline. Journal of Physiology 1937a; 90:1-14.</p>
<p>Blaschko H, Richter D, Schlossmann H. The oxidation of adrenaline and other amines. Biochemical Journal 1937b; 31: 2187-96.</p>
<p>Bowman RL, Caulfield PA, Udenfriend S. Spectrophotofluorometry in the visible and ultraviolet spectrum. Science 1955; 122: 32-3.</p>
<p>Brodie BB, Pletscher A, Shore P. Possible role of serotonin in brain function and serotonin action. J Pharmacol Exp Ther 1956; 116: 9. </p>
<p>Brodie BB, Shore P, Pletscher A. Limitation of serotonin releasing activity to those alkaloids possessing tranquilizing action. Science 1956; 123: 992 – 3. </p>
<p>Chorine V. <i>Action de l’amide nicotinique sur les bacilles du genre microbacterium</i>. CR de l’Academie des Sciences (Paris) 1945; 220; 150 – 1. </p>
<p>Delay J, Laine B, Buisson JF. <i>Note concernant l’action de l‘isonicotinylhydrazide dans le traitement des etats depressifs.</i> Ann Medico Psychol 1952; 110: 6689 -99.</p>
<p>Elliott TR. The action of adrenalin. J Physiol 1905; 32:&nbsp; 401-2.</p>
<p>Erspamer V, Asero B. Identification of enteramine, specific hormone of enterochromaffin cells as 5-hydroxtryptamine. Nature 1952; 169: 800-1</p>
<p>Erspamer V, Vialli M. <i>Ricerche sul secreto delle cellule enterocromaffini</i>. Boll d Soc Med-chir Pavia 1937; 51: 357-63.</p>
<p>Euler v US. A specific sympathomimetic ergone in adrenergic nerve fibers (sympathin) and its relation to adrenaline and noradrenaline. Acta Physiol Scand 1946; 12: 73-9. </p>
<p>Flaherty JA. The psychiatric use of isonicotinic acid hydrazide: a case report. Delaware Med J 1952; 24: 298-300. </p>
<p>Fox HH, Gibas JT. Synthetic tuberculostats. VII. Monoalkyl derivatives of isonicotinylhdrazine. J Org Chem 1953; 18: 994 - 1002.&nbsp; </p>
<p>Hare MLC. Tyramine oxidase: A new enzyme system in the liver. Biochem J 1928; 22: 968-79.</p>
<p>Knoll J. Felix Blaschko. inhn.org. Profiles. July 17, 2014. </p>
<p>Kopin IJ. My first ten years at INHN: The dawn of psychopharmacology. In Ban TA, Ucha Udabe R, editors. The Neurotransmitter Era in Neuropsychopharmacology. Buenos Aires: Polemos; 2006, p. 39 - 50.</p>
<p>Pletscher A. <i>Beeinflussung des 5-Hydroxytryptamin – stoffwechsels im Gehirn durch Isonikotinsauerehydrazide</i>. Experientia 1956; 12: 479 – 80.</p>
<p>Pletscher A. On the eve of the neurotransmitter era in biological psychiatry. In: Ban TA, Healy D, Shorter E, editors.&nbsp; The Rise of Psychopharmacology and the Story of CINP. Budapest: Animula; 1998. p. 110-5.</p>
<p>Pletscher A. From inside the pharmaceutical industry. (Roche). In Ban TA, Healy D, Shorter E, editors. Reflections on Twentieth-Century Psychopharmacology. Budapest: Animula; 2004, p. 19-27. </p>
<p>Pletscher A. The dawn of the neurotransmitter era in neuropsychopharmacology. In Ban TA, Ucha Udabe R, editors. The Neurotransmitter Era in Neuropsychopharmacology. Buenos Aires: Polemos; 2006, p. 28 - 37.</p>
<p>Pletscher A interviewed by Thomas A. Ban. In: Sulser F, editor. Neuropharmacology. (In Ban TA, editor. An Oral History of Neuropsychopharmacology The First Fifty Years Peer Interviews. Volume Three). Brentwood: American College of Neuropsychopharmacology; 2011, p. 420 – 33.&nbsp;&nbsp; </p>
<p>Pletscher A interviewed by Andrea Tone. In: Blackwell B, editor. Update. (In: Ban TA, editor. An Oral History of Neuropsychopharmacology The First Fifty Years Peer Interviews. Volume Nine). Brentwood: American College of Neuropsychopharmacology; 2011, p. 27- -5.&nbsp;&nbsp; </p>
<p>Pletscher A, Shore P. Brodie BB. Serotonin release as a possible mechanism of reserpine action. Science 1955; 122:374 - 5.&nbsp; </p>
<p>Pletscher A, Shore P. Brodie BB. Serotonin release as a modulator of reserpine action in the brain. J Parmacol Exp Therap 1956; 116: 84 -9.&nbsp; </p>
<p>Pugh C, Quastel JH. Oxidation of aliphatic amines by brain and other tissues.&nbsp; Biochem J 1937; 31: 286-91.</p>
<p>Rapport MM, Green AA, Page IH. Crystalline serotonin. Science 1948; 108: 329-30.</p>
<p>Robitzek EH, Selikoff IJ, Orenstein GG. Toxicity of hydrazine derivatives of isonicotinic acid in the chemotherapy of human tuberculosis. Q Bull Sea View Hosp 1952; 13:&nbsp; 27-37.</p>
<p>Stevens LT, Lee FS. Action of intermittent pressure and of defibrinated blood upon blood vessels of frog. Johns Hopkins Bulletin 1884; 3: 99-100.</p>
<p>Sulser F. Introduction and Dramatis personae. In Sulser F, editor. Neuropharmacology. (In: Ban TA, editor. An Oral History of Neuropsychopharmacology The First Fifty Years Peer Interviews. Volume Three). Brentwood: American College of Neuropsychopharmacology; 2011, p. x – lx.&nbsp;&nbsp; </p>
<p>Twarog BM, Page IH. Serotonin content of some mammalian tissues and urine and a method for its determination.&nbsp; Am J Physiol 1953; 175: 157-61.</p>
<p>Vogt M. Concentration of sympathin in different parts of central nervous system under normal conditions and after administration of drugs. J Physiol 1954; 123: 451-81.</p>
<p>Zeller EA. <i>Üeber den enzymatischen Abbau von Histamin und Diaminen</i>. Helvetia Chem Acta 1938; 21: 881-90.</p>
<p>Zeller EA, Barsky J. In vivo inhibition of liver and brain monoamine oxidase by 1 - isonicotinyl – isopropyl hydrazine. Proc Exp Biol 1952; 81: 459 – 61.</p>
<p>Zeller EA, Barsky J, Berman ER, Fouts JR. Action of isonicotinic acid hydrazide and related compounds on enzymes involved in the autonomic nervous system. J Pharmacol Exp Ther 1952; 106: 427-8. </p>
<p><a href="IMAGES/BAN_BULLETIN_15___2_AUTOBIOGRAP.PDF" class="download">&nbsp;CLICK HERE TO OPEN THE DOCUMENT</a></p>
<p>April 26, 2018</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><b><br /> <br /> </b></p></div><!--DMAILER_SECTION_BOUNDARY_END--><!--TYPO3SEARCH_end--></div>
				</div>
				<div id="ie_clearing">&nbsp;</div>
			</div>
		</div>
		<div id="footer">&copy; INHN 2012-2022 ::: INHN Central Office  · Av. Sagrada Familia Esq Nazaret · Córdoba, Córdoba X5000 · Argentina  ::: email: inhn@inhn.org</div>
	</div>
</div>





<script src="IMAGES/URCHIN.JS" type="text/javascript">
</script>
<script type="text/javascript">
_uacct = "UA-39727086-1";
urchinTracker();
</script>
</body>
</html>